Polymorphisms of genes related to phase II metabolism and resistance to clopidogrel.
Abdullah AlkattanAhmed AlkhalifahEman AlsalameenFatimah AlghanimNashwa RadwanPublished in: Pharmacogenomics (2021)
Clopidogrel is an antiplatelet drug commonly used to prevent coagulation. This review aimed to investigate the effect of polymorphisms of G6PD, GCLC, GCLM, GSS, GST, GSR, HK and GLRX genes on clopidogrel during phase II metabolism through exploring previous studies. The results revealed that low glutathione plasma levels caused by several alleles related to these genes could affect the bioactivation process of the clopidogrel prodrug, making it unable to inhibit platelet aggregation perfectly and thus leading to severe consequences in patients with a high risk of blood coagulation. However, the study recommends platelet reactivity tests to predict clopidogrel efficacy rather than studying gene mutations, as most of these mutations are rare and other nongenetic factors could affect the drug's efficacy.
Keyphrases
- phase ii
- acute coronary syndrome
- percutaneous coronary intervention
- antiplatelet therapy
- clinical trial
- open label
- genome wide
- bioinformatics analysis
- genome wide identification
- phase iii
- placebo controlled
- coronary artery disease
- drug induced
- gene expression
- early onset
- randomized controlled trial
- cancer therapy
- study protocol
- atrial fibrillation
- case control
- drug delivery
- endothelial cells